U.S. Physical Therapy, Inc. (USPH) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. U.S. Physical Therapy, Inc. operates through two segments: Physical Therapy Operations (outpatient clinics and home-care) and Industrial Injury Prevention (IIP) services. As of June 30, 2025, the company owned or managed 768 clinics, an increase from 722 in the prior year period, driven by the addition of six clinics and the closure of four in Q2 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $197.3 million | $167.2 million | $381.1 million | $322.9 million |
| Net Income (Total) | $17.7 million | $11.7 million | $31.2 million | $23.3 million |
| Net Income (USPH Shareholders) | $12.4 million | $7.5 million | $22.3 million | $15.6 million |
| Diluted EPS (USPH) | $0.58 | $0.47 | $1.38 | $0.93 |
| Operating Income | $24.9 million | $15.6 million | $44.6 million | $30.5 million |
| Adjusted EBITDA (Non-GAAP) | $26.9 million | $22.1 million | $46.4 million | $38.9 million |
| Cash & Equivalents | $34.1 million | $112.9 million | $34.1 million | $112.9 million |
| Total Debt (Principal) | $160.9 million | $154.6 million | $160.9 million | $154.6 million |
| Available Credit | $150.5 million | $164.0 million | $150.5 million | $164.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 18.0% year-over-year for Q2 2025, driven by a 16.7% increase in patient visits and a slight increase in net rate per visit ($105.33 vs. $105.05), despite a 2.9% Medicare reimbursement reduction effective Jan 1, 2025.
- Profitability: Operating income surged 60.2% to $24.9 million, aided by a $4.8 million swing in the fair value of contingent earn-out consideration (a gain of $0.8 million in 2025 vs. a loss of $4.0 million in 2024).
- Acquisitions: The company completed two significant acquisitions in the first half of 2025: a 65% interest in a 3-clinic practice (Feb 2025) and a 40% interest in a home-care practice via its Metro subsidiary (April 2025).
- Cash Position: Cash and cash equivalents decreased to $34.1 million from $112.9 million in the prior year, reflecting deployment of capital for acquisitions and dividends.
Guidance, Outlook, and Risks
- Capital Allocation: The Board approved a $25 million share repurchase program effective August 5, 2025, expiring December 31, 2026. A quarterly dividend of $0.45 per share was declared, payable September 12, 2025.
- Outlook: Management expects to continue acquiring multi-clinic practices and IIP businesses. Corporate office costs are elevated due to a new financial and HR system implementation expected to continue through 2026.
- Risks & Contingencies:
- Regulatory: Ongoing exposure to Medicare reimbursement rate changes and potential audits/investigations by CMS and the Department of Justice.
- Redeemable Non-Controlling Interest (RNCI): The company holds significant RNCI ($263.3 million) which may require future cash outflows if partners exercise put rights upon employment termination.
- Interest Rates: Variable rate debt exposes the company to interest rate fluctuations, partially mitigated by a $150 million interest rate swap.
Investor Verification Checklist
- Visit Volume vs. Rate: Verify if the increase in net rate per visit ($105.33) is sustainable given the 2.9% Medicare cut and commercial payer contract negotiations.
- Non-GAAP Reconciliations: Review the impact of the $5.6 million gain on contingent earn-out consideration on operating income; this is a non-cash item that significantly boosted reported earnings.
- Debt Covenants: Confirm continued compliance with the Consolidated Leverage Ratio and Fixed Charge Coverage Ratio covenants under the $325 million Credit Agreement.
- RNCI Obligations: Assess the potential cash impact of the $263.3 million redeemable non-controlling interest balance if employment terminations trigger put rights.
- Acquisition Integration: Monitor the performance of the Metro home-care acquisition and the 3-clinic practice acquired in Q1/Q2 2025.